BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Etoposide: trial readouts and FDA decisions

4 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 4 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Merck Sharp & Dohme LLC, Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd., Nanjing Leads Biolabs Co.,Ltd, CStone Pharmaceuticals, Shanghai Runshi Pharmaceutical Technology Co., Ltd, AstraZeneca, Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P1/P2Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.NCT07136285 Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLCSCLC, Extensive Stagerecruiting27
2026-12-28 est.P1/P2Nanjing Leads Biolabs Co.,LtdNCT06157827 A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine CarcinomaAdvanced Neuroendocrine Carcinomarecruiting178
2027-01 est.P1/P2CStone PharmaceuticalsNCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid TumorsAdvanced Solid Tumorsrecruiting800
2027-02-12 est.P2Merck Sharp & Dohme LLC MRKNCT03407144 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)Hodgkin Lymphomaactive not recruiting340

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-13 est.P1/P2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06682611 Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.Unresectable Locally Advanced or Metastatic Solid Tumorsnot yet recruiting380
2026-07-10P3AstraZeneca AZNNCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete TuNon-small Cell Lung Canceractive not recruiting25
2026-07 est.P1/P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT06372626 Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.Neuroendocrine Carcinomaunknown93
2026-06-15P3Merck Sharp & Dohme LLC MRKNCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent ChemoraCarcinoma, Non-Small-Cell Lungcompleted610

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.